ISRCTN32507927已完成未知
The chronic care for age-related macular degeneration study (CHARMED): A randomised controlled trial
niversity Hospital Zurich (Universitaetsspital Zurich) (Switzerland)0 个研究点目标入组 352 人开始时间: 2011年3月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 352
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female patients with neovascular age-related macular degeneration (wet AMD)
- •2. Eligible for a therapy with anti-angiogenic drug
- •3. Visual acuity less than equal to 0.05 (assessed by Early Treatment Diabetic Retinopathy Study ETDRS charts)
- •4. Age more than 50 years
- •5. Written informed consent given before any study related procedure is performed
排除标准
- •1. Serious general or psychological illness (advanced malignant tumours, serious depressive episodes, evidence of dementia)
- •2. Insufficient language skills (informed consent, patient information and questionnaires will be provided in German and French)
- •3. Patients with any invasive medical treatment for wet AMD in the past
研究者
相似试验
已完成
1 期
The effect of saffron supplementation on vision in patients with early dry age-related macular degeneratioAge-related macular degenerationACTRN12612000729820The University of Sydney100
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-FRBayer HealthCare AG268
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-GBBayer AG287
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)EUCTR2014-003132-39-ESBayer HealthCare AG268
进行中（未招募）
1 期
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)eovascular age-related macular degeneration (nAMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2014-003132-39-ITBAYER AG287